Emerging studies suggest Retatru tide , a dual stimulator targeting both incretin and glucose-dependent insulinotropic polypeptide , could represent a promising development for body loss . Early clinical tests have indicated substantial losses in abdominal fat , possibly exceeding other weight-loss medications . Despite this, additional assessment